COR: Bladerunner, I've had some professional experience with COR in addition to the tracking. Unfortunately, I can't disclose any specicic information, but think that it is safe to say that it was in regard to a trial that has since been discontinued by the co.
I await further developments and will continue to watch COR with interest as they continue to tout drugs in the pipeline that are in my line of work.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.